Vancouver, Canada, November 4th, 2025, FinanceWire
USA News Group News Commentary – Healthcare’s embrace of AI is moving from pilot to standard practice across hospitals, clinics, and payors[1]. Adding fuel, the FDA is now inviting input on how to track real-world performance of AI tools, a step that could speed responsible rollouts and wider coverage for AI-enabled devices[2]. That momentum points investors toward companies building practical, reimbursable solutions across triage, oncology insights, and revenue integrity, including Teladoc Health (NYSE: TDOC), Compugen Ltd. (NASDAQ: CGEN), SOPHiA GENETICS (NASDAQ: SOPH), and Claritev Corporation (NYSE: CTEV) and Aleen Inc. (CSE: ALEN-U), a Canadian technology company operating in the digital wellness space.
Analysts now project digital health to reach $2.69 trillion by 2035 at a 22.55% CAGR, underscoring how AI-powered platforms could drive the bulk of that growth by the numbers[3]. Adoption is also accelerating on the ground, with payors and providers reporting real gains in care management and documentation as AI tools scale across front lines in new surveys[4].
Aleen Inc. (CSE: ALEN-U) is making waves in the digital wellness sector. The Canadian technology company, which went public on the Canadian Securities Exchange in June 2025, has developed an AI platform designed to help users understand their user inputs and wellness indicators. Aleen’s system allows individuals to enter their data and receive personalized wellness insights, without providing medical diagnoses or replacing professional medical advice.
Based in Ontario, Aleen Inc. operates in a rapidly expanding market. The global digital wellness sector is currently valued at approximately $12.87 billion in 2025 and is projected to grow to $45.65 billion by 2034, representing annual growth of 15.1%. With about 57% of consumers now using digital apps and wearable devices to monitor their well-being, Aleen Inc. is positioned to capture a portion of this expanding demand.
Aleen Inc.’s main product, the Aleen AI system, can be accessed in two ways. Users can visit the Aleen website for free wellness insights, which helps raise awareness and encourages active engagement with personal well-being. Businesses can integrate Aleen Inc.’s technology via its API, allowing wellness apps and digital platforms to embed the AI-powered insights into their own services. The API supports wellness decision-making, not clinical diagnostics.
The company generates revenue through its API offerings, which are available through two pricing models: a per-call option for businesses paying only for requests used, and a monthly subscription for consistent access. This flexible approach allows Aleen Inc. to serve both small and enterprise clients.
Looking ahead to 2026, Aleen Inc. has announced ambitious expansion plans. The company is preparing to launch personal user accounts that will allow individuals to securely store and organize their wellness information in one place. Additionally, the company plans to introduce smart analytics features that will help users identify patterns in their wellness data and make more informed decisions about their well-being.
To fund these initiatives, Aleen Inc. is currently seeking between $20 million and $30 million in strategic investment. The company plans to allocate 35% of these funds toward technology development, including enhancements to its AI algorithms and expansion of its wellness indicator database. Another 30% would go toward sales and marketing efforts, including global outreach to potential business partners. Product expansion would receive 20% of the funding for developing mobile apps and specialized modules for corporate wellness programs.
The company emphasizes that its platform is designed for preliminary wellness insights only and is not intended to replace consultations with healthcare professionals. Aleen Inc. does not provide medical diagnoses and is not regulated as a medical device by the FDA or other health authorities. Instead, the platform serves as a first step in helping people understand their user inputs and wellness indicators, supporting informed wellness decisions.
With 12,643,300 common shares currently issued and outstanding, Aleen Inc. continues to build its presence in the digital wellness space under the leadership of CEO Inna Aksman.
Teladoc Health (NYSE: TDOC) has launched a workplace safety capability for its AI-enabled Clarity monitoring solution, addressing the growing crisis of healthcare workplace violence that costs hospitals over $18 billion annually. The new technology uses video and audio analysis to detect facial expressions, threatening gestures, and aggressive language, providing early intervention alerts to care teams before incidents escalate.
“Healthcare workplace violence is a persistent and growing threat impacting care team safety, patient wellbeing, and health system operations,” said Andy Puterbaugh, President, Hospital and Health Systems at Teladoc Health. “While traditional tools are often reactive—relying on human vigilance or panic buttons—our new workforce safety capability is purpose-built to transform insights into action, using AI to empower early intervention and improve the safety of everyone in the care setting.”
The solution will be implemented with select hospitals and health systems in Q1 2026 as part of Teladoc Health’s partner development program. Healthcare workers currently face five times higher workplace violence risk compared to other industries, with over 80% of nurses reporting they have experienced workplace violence.
Compugen Ltd. (NASDAQ: CGEN) announced a pooled analysis of COM701 across three Phase 1 trials involving 60 patients with platinum resistant ovarian cancer, demonstrating consistent, durable responses in heavily pretreated patients. The clinical-stage cancer immunotherapy company utilizes AI and machine learning powered predictive computational target discovery to identify new drug targets and biological pathways.
“The pooled analysis demonstrates that COM701 was well tolerated and showed consistent, durable responses in patients with heavily pretreated platinum-resistant ovarian cancer – particularly in those without liver metastases, representing patients with lower disease burden and potentially less immunosuppressive tumor microenvironment,” said Dr. Oladapo Yeku, Assistant Professor of Medicine at Harvard Medical School and Director of Translational Research, Gynecologic Oncology Program at Massachusetts General Hospital. “The results of the analysis support the rationale for evaluating COM701 as maintenance therapy in earlier lines of treatment.”
Compugen is currently conducting the MAIA-ovarian trial assessing COM701 monotherapy as maintenance treatment in relapsed platinum-sensitive ovarian cancer, with sites activated in the United States, Israel, and France. The company anticipates an interim analysis at year end 2026 and expects its cash position will support operations well into 2027.
SOPHiA GENETICS (NASDAQ: SOPH) has launched SOPHiA DDM Digital Twins, breakthrough AI-powered technology that creates dynamic virtual representations of individual cancer patients to simulate treatment outcomes and disease trajectories in real time. The platform uses each patient’s unique clinical, biological, imaging, and genomic data to generate computational replicas, enabling oncologists to explore potential treatment strategies virtually before making bedside decisions.
“Cancer is constantly evolving, and static snapshots are no longer enough,” said Jurgi Camblong, Ph.D., Co-Founder & CEO of SOPHiA GENETICS. “With SOPHiA DDM Digital Twins, we can create advanced AI models based on our broad patient network, accelerating research, sharpening clinical decisions, and turning today’s insights into tomorrow’s breakthroughs. This reflects our ambition to make data-driven medicine the global standard of care.”
The technology leverages the collective intelligence of the SOPHiA GENETICS community and continuously evolves as new data becomes available. The platform is launching initially for lung cancer with additional cancer types planned for coming months.
Claritev Corporation (NYSE: CTEV) has forged a strategic partnership with iO Health to deliver Optima AI across the Middle East and North Africa region, securing exclusive rights to license, integrate, and resell the AI-powered revenue cycle management platform. The technology helps healthcare providers reduce claim denials, optimize workflows, and improve financial outcomes while serving over 700 healthcare payors, 100,000 employers, and 60 million consumers.
“This strategic relationship marks a pivotal step in Claritev’s global expansion strategy,” said Travis Dalton, President & CEO of Claritev. “Together with iO Health, we are bringing cutting-edge AI technology to healthcare providers and payors in MENA, with the goal of helping them improve financial health while reducing administrative burden.”
iO Health, founded in 2021, currently processes and optimizes insights from more than 32 million patient records across the MENA region through its proprietary cognitive AI. Both companies will work closely on implementation, integration, and ongoing support to maximize value for healthcare organizations throughout the region.
Article Sources: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/
About USA News Group
USA News Group: “Your Specialist Source for Market News and Analysis”. In today’s fast-paced world, staying informed about the events and issues shaping the nation has never been more important. That’s where USA Today comes in – one-stop destination for comprehensive, up-to-the-minute coverage of news, politics, business, markets and more from a unique perspective.
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Aleen Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Aleen Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Aleen Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Aleen Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Aleen’s solutions operate within the wellness domain and are not subject to FDA or Health Canada approval.
Sources:
- https://www.managedhealthcareexecutive.com/view/healthcare-s-embrace-of-ai-october-2025-cover-story
- https://www.fda.gov/medical-devices/digital-health-center-excellence/request-public-comment-measuring-and-evaluating-artificial-intelligence-enabled-medical-device
- https://www.prnewswire.com/news-releases/digital-health-market-size-to-worth-usd-2688-billion-by-2035-at-22-55-cagr–vantage-market-research-302584686.html
- https://www.forbes.com/sites/sachinjain/2025/10/21/ai-adoption-in-healthcare-is-surging-what-a-new-report-reveals/